Objective For major depressive disorder (MDD), there has been a lack of neuroimaging
markers of efficacy of pharmacological treatment. In this study, we aimed to explore the …

Background Our study aimed to explore the abnormal spontaneous brain activity by regional
homogeneity (ReHo) and its association with cognitive function to understand the …

Objective Previous work exhibited different brain grey matter volume (GMV) changes
between patients with early adult onset depression (EOD, age 18–29) and later adult onset …

Background Neurobiological mechanisms underlying the recurrence of major depressive
disorder (MDD) at different ages are unclear, and this study used the regional homogeneity …

Background Anomalies in regional homogeneity (ReHo) have been documented in patients
with major depressive disorder (MDD) and sleep disturbances (SDs). This investigation …

This study aims to identify and characterize neurobiological markers for major depressive
disorder (MDD) from resting-state brain functional MRI. We examined the abnormality in the …

Objective A resting-state functional magnetic resonance imaging study (fMRI) to investigate
pretreatment regional differences in brain function, in patients with early treatment …

Objective Predefining the most effective treatment for patients with depressive disorders
remains a problem. We will examine the differential brain regions of gray matter (GM) in …

Abstract Treatment‐refractory depression (TRD) represents a large proportion of the
depressive population, yet has seldom been investigated using advanced imaging …

BACKGROUND: Patients with treatment-resistant depression (TRD) and those with
treatment-sensitive depression (TSD) responded to antidepressants differently. Previous …